Uterine sarcoma dissemination during myomectomy: If not “acceptable collateral damage,” is it possible to mitigate the risk?

Author： Judson Ian R.   Miah Aisha B.  

Publisher： Blackwell Publishing

E-ISSN： 1097-0142|120|20|3100-3102

ISSN： 0008-543X

Source： Cancer, Vol.120, Iss.20, 2014-10, pp. : 3100-3102

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Related content

Repairing collateral damage in MS

By  

Inpharma, Vol. 1, Iss. 1389, 2003-01 ,pp. : 9-9

Adis International

Access to resources Recommend Favorite

Tamoxifen associated with uterine sarcoma

By  

Inpharma, Vol. 1, Iss. 1342, 2002-01 ,pp. : 21-21

Adis International

Access to resources Recommend Favorite

Tolerance Induction During Therapy with Long-Acting Nitrates: How Extensive is the “Collateral Damage”?

By Horowitz John  

Cardiovascular Drugs and Therapy, Vol. 18, Iss. 1, 2004-01 ,pp. : 11-12

Springer Publishing Company

Access to resources Recommend Favorite

Is addiction's collateral damage culturally invariant?

By Humphreys Keith  

Addiction Research and Theory, Vol. 14, Iss. 6, 2006-12 ,pp. : 647-648

Informa Healthcare

Access to resources Recommend Favorite

Long-Standing Statin Therapy and the Risk of New-Onset Diabetes in the Elderly: Collateral Damage Caused by Preventive Medicine?

By Mascitelli Luca  

Drugs & Aging, Vol. 29, Iss. 1, 2012-01 ,pp. : 9-13

Adis International

Access to resources Recommend Favorite